Home » Stocks » NBSE

NeuBase Therapeutics, Inc. (NBSE)

Stock Price: $9.22 USD -0.66 (-6.68%)
Updated Jan 27, 2021 3:47 PM EST - Market open
Market Cap 228.99M
Revenue (ttm) n/a
Net Income (ttm) -17.38M
Shares Out 19.62M
EPS (ttm) -3.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $9.22
Previous Close $9.88
Change ($) -0.66
Change (%) -6.68%
Day's Open 9.57
Day's Range 9.11 - 10.50
Day's Volume 370,747
52-Week Range 4.77 - 11.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 4 days ago

One of its investors praised the company in a quarterly performance update.

GuruFocus - 5 days ago

David Einhorn (Trades, Portfolio)'s hedge fund, Greenlight Capital, ended 2020 on a high note. After a rough start to the year, Greenlight added 25% in the fourth quarter of 2020, making it th...

Other stocks mentioned: GRBK, HON, REZI
GlobeNewsWire - 2 weeks ago

PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new cl...

GlobeNewsWire - 1 month ago

Data presented throughout 2020 have validated the potential of the PATrOL™ platform to develop highly targeted therapies that increase, decrease or change causal protein function

Accesswire - 1 month ago

Registration For This FREE Tribe Public Presentation and Q&A Event Is Now Open at NeuBase22.TribePublic.com SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2020 / Tribe Public announced today th...

GlobeNewsWire - 2 months ago

PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new cl...

GlobeNewsWire - 2 months ago

PITTSBURGH, Nov. 10, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new cl...

GlobeNewsWire - 3 months ago

PITTSBURGH, Sept. 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new...

GlobeNewsWire - 4 months ago

PITTSBURGH, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new...

GlobeNewsWire - 5 months ago

Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic Medicines

Zacks Investment Research - 7 months ago

NeuBase (NBSE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

About NBSE

NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase ... [Read more...]

Industry
Biotechnology
CEO
Dietrich Stephan
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
NBSE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for NBSE stock is "Strong Buy." The 12-month stock price forecast is 15.67, which is an increase of 69.96% from the latest price.

Price Target
$15.67
(69.96% upside)
Analyst Consensus: Strong Buy